Tuesday - March 17, 2026
Kerendia Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients With Non-Diabetic Chronic Kidney Disease
March 17, 2026
WHIPPANY, New Jersey, March 17 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news:

* * *

KERENDIA(R) (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

* KERENDIA(R) (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerula . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products